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Selection of a therapy for a patient with alopecia areata
(AA) is frequently based on the age of the patient,
disease extent, perhaps disease duration, patient
expectations, cost of therapy in terms of time commit-
ment, and financial resources, as well as the results of
screening laboratory studies that rule out the presence
of other co-morbidities such as anemia, low iron
stores, thyroid abnormalities, low vitamin D, or other
autoimmune diseases. Although there is currently no
cure for AA and no universally proven therapy that
induces and sustains remission, many therapies are
available which can be of benefit to both affected
children and adults. Before selecting a treatment for
patients with extensive long-standing AA, a scalp
biopsy may provide useful information about the
degree of inflammation and follicle differentiation.
Recent clinical and translational research observations
with the systemic Janus kinase (JAK) inhibitors and
interleukin-2 (IL-2) have excited the clinical and AA
patient communities and have led to clinical trials, as
well as to the off-label use of these more expensive
and targeted systemic therapies.
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CURRENT TREATMENTS
Most physicians generally prefer topical therapy for AA but
current treatment of patchy and extensive AA can include
many modalities as summarized in Tables 1 and 2, respec-
tively (Delmere et al., 2008; Hordinsky, 2011; Castela et al.,
2014; Craiglow and King, 2014; Xing et al., 2014). However,
in a recent analysis of the biomedical literature database,
PubMed using the terms ‘‘randomized controlled trials’’ and
‘‘alopecia areata’’ only 29 trials, which strictly met these
criteria were found. These studies and treatments (Table 3)
were reviewed and analyzed using the American College of
Physicians guideline grading system (Hordinsky and Donati,
2014). The assessment was that the majority of these
studies were only of moderate quality. At the same
time, a number of treatments were found to be effective,
e.g., topical and oral corticosteroids and the sensitizing agents
diphenylcyclopropenone (DPCP) and dinitrochlorobenzene.
Most studies though had major limitations that hindered the
interpretation of study results. Until robust clinical research
studies are completed, there will be ongoing debate regarding
established therapies, as well as the risks and benefits, cost,
and sustainability of new approaches. This is particularly true
in the case of children with AA where there has been very
little clinical research.
TREATMENT OF AA IN CHILDREN WITH THERAPIES
COMMONLY USED IN ADULTS: TOPICAL, INTRALESIONAL
(IL), ORAL, OR INTRAVENOUS STEROIDS, TOPICAL
MINOXIDIL, LIGHT AND IMMUNOTHERAPY
Issues with the current pediatric literature for AA are that few
studies are controlled and there is no way to prove that
treatment is better than placebo/natural course of the disease.
Moreover, measuring outcomes is not standardized and often
not detailed and many studies include no follow-up. As with
adults, topical steroids are often the first-line approach for
limited patchy AA. Lenane et al. (2014) demonstrated that
higher potency topical steroids might be most beneficial for
pediatric AA patients. Clobetasol propionate 0.05% cream
and hydrocortisone 1% cream were compared in 42 patients
and the investigators found that the clobetasol group had a
statistically significant greater amount of regrowth after 24
weeks. A 2004 case series also showed better responses to
high-potency steroids. Of 4 patients, 2 were treated with
clobetasol and both had complete resolution after about 9
months. Despite widespread use, there still is not much more
data in children with AA.
The use of intralesional (IL) steroids is a mainstay of
therapy of AA for adults, although the concentration and total
dose to be safely delivered continue to be debated. In
children, the use of IL steroids is more limited most likely
because of fear of injections and pain. There is data though
from a 2002 chart review from Singapore which showed that
160/248 (65%) of children had 450% improvement after 12
weeks, 211/248 (85%) with 450% improvement after 24
weeks; however, 32 stopped injections because of pain (Tan
et al., 2002). There are also no good studies in children on the
use of oral corticosteroids. Interestingly, both trials and chart
reviews have been published on the administration of high-
dose pulse methylprednisolone in children with the key points
being that this approach may be useful in acute crises of hair
loss but is associated with a high relapse rate and need for
careful monitoring (Kiesch et al., 1997; Sharma and
Muralidhar 1998; Hubiche et al., 2008).
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As with adults, topical immunotherapy may benefit children
with chronic and extensive AA but requires frequent visits,
may be more difficult for children to tolerate and at this time,
there is no Food and Drug Administration (FDA) formulation
approved for use in the USA (Hull et al., 1991; Salsberg and
Donovan, 2012). Topical minoxidil is used in children to
enhance anagen differentiation but noteworthy is that there
are no pediatric trials or chart reviews; only case reports are
available for review.
HOLISTIC MANAGEMENT OF PEDIATRIC AND ADULT AA
Management of childhood AA is complicated by the child’s
psychosocial well-being, as well as parental anxiety, frustra-
tion, guilt, and expectations. In some cases, no treatment may
be an option for both children and adults.
FUTURE
Numerous treatments are available for adults and children
with AA but most studies supporting use of these treatments in
children have been completed in adults. More research needs
to be done for pediatric AA using the Alopecia Areata
Investigational Guidelines (both on novel new treatments
and established adult treatments) with detailed outcome
measurements along with follow-up data (Olsen et al.,
1999). The new clinical and translational research
observations and clinical trials with the Jak inhibitors and IL-
2 have excited the clinical and AA patient communities and
all look forward to moving from the trials and off-label use to
focused use of these medications either orally, systemically, or
topically in a coordinated, cost effective, safe manner in both
children and adults.
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